# Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

> **NCT04775680** · PHASE1,PHASE2 · TERMINATED · sponsor: **Adagene (Suzhou) Limited** · enrollment: 25 (actual)

## Conditions studied

- Solid Tumor
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** ADG106 injection
- **BIOLOGICAL:** PD-1 antibody injection

## Key facts

- **NCT ID:** NCT04775680
- **Lead sponsor:** Adagene (Suzhou) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-11
- **Primary completion:** 2023-02-09
- **Final completion:** 2023-02-09
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical benefit of enrolled subjects was limited and further development of ADG106 was reconsidered.
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775680, "Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04775680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*